No­var­tis teams up with Ox­ford re­searchers to crunch big da­ta in­to clin­i­cal in­sights

Since Vas Narasimhan’s Day 1 as CEO of No­var­tis, he has cham­pi­oned da­ta sci­ence and dig­i­tal tech­nolo­gies as a key pri­or­i­ty at the phar­ma gi­ant. Al­most a year in­to his tenure, in a re­cent con­ver­sa­tion with the tech VC firm An­dreessen Horowitz, he high­light­ed the abil­i­ties to an­a­lyze pathol­o­gy im­ages and cen­tral­ize clin­i­cal tri­al plan­ning as two promis­ing ap­pli­ca­tions of ma­chine learn­ing.

But, he ad­mit­ted, there are ar­eas where it’s “sim­ply not met up”:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER